Monte Rosa Therapeutics, Inc. (GLUE) – What Are Analysts Thinking About This Stock?

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) has been given an average rating of “Moderate Buy” by the twelve research firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $26.44.

A number of research firms have recently commented on GLUE. Wells Fargo & Company reduced their target price on shares of Monte Rosa Therapeutics from $27.00 to $25.00 and set an “overweight” rating on the stock in a research report on Friday, November 6th. Wall Street Zen upgraded shares of Monte Rosa Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 7th. Raymond James Financial set a $25.00 target price on shares of Monte Rosa Therapeutics in a research report on Monday, October 5th. HC Wainwright assumed coverage on shares of Monte Rosa Therapeutics in a research note on Thursday, October 1st. They set a “buy” rating and a $25.00 target price on the stock. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Monte Rosa Therapeutics from $31.00 to $27.00 and set an “overweight” rating for the company in a report on Friday, August 7th.

Institutional Trading of Monte Rosa Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in GLUE. BlackRock Inc. acquired a new stake in shares of Monte Rosa Therapeutics during the 2nd quarter valued at $165,603,000. Jupiter Topco LLC acquired a new stake in shares of Monte Rosa Therapeutics during the second quarter valued at approximately $25,965,000. Opaleye Management Inc. purchased a new stake in shares of Monte Rosa Therapeutics in the 2nd quarter valued at approximately $18,029,000. Janus Henderson Group PLC acquired a new position in Monte Rosa Therapeutics in the 1st quarter worth approximately $11,294,000. Finally, Nantahala Capital Management LLC purchased a new position in Monte Rosa Therapeutics during the 2nd quarter worth approximately $15,778,231. 79.96% of the stock is owned by institutional investors and hedge funds.

Monte Rosa Therapeutics Price Performance

Shares of NASDAQ GLUE opened at $10.31 on Friday. The company has a market capitalization of $880.99 million, a PE ratio of -7.36 and a beta of 1.40. Monte Rosa Therapeutics has a 12-month low of $9.68 and a 12-month high of $25.77. The firm’s 50-day moving average is $11.50 and its two-hundred day moving average is $16.90.

Monte Rosa Therapeutics (NASDAQ:GLUE) last issued its quarterly earnings results on Thursday, November 5th. The company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.24. The company had revenue of $54.37 million for the quarter, compared to analyst estimates of $33.87 million. Monte Rosa Therapeutics had a negative return on equity of 30.14% and a negative net margin of 186.24%. On average, analysts forecast that Monte Rosa Therapeutics will post -0.94 EPS for the current fiscal year.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing molecular glue degraders, medicines designed to direct disease-associated proteins for disposal by the cell. Its discovery platform combines computational and experimental methods to identify and develop these potential treatments. The company’s research has included programs for cancer and immune-mediated diseases. Its pipeline includes MRT-6160, a VAV1 degrader being developed for autoimmune and inflammatory conditions, and MRT-8102, an investigational degrader targeting the NLRP3 inflammasome pathway.